Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Anti-GATA3 gene-therapy (Primary)
- Indications Allergic asthma; Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors sterna biologicals
- 07 Apr 2017 Results a pre-specified subgroup analysis from this trial were published in the Journal of Allergy and Clinical Immunology 2017, as reported in a Sterna Biologicals Media Release.
- 07 Apr 2017 Results a pre-specified subgroup analysis published in the Sterna Biologicals Media Release
- 17 May 2015 According to a Sterna Biologicals media release, full analysis of this trial was presented at the American Thoracic Society (ATS) 2015 International Conference and concurrently, the paper was published in the New England Journal of Medicine (Krug et al., 2015).